BioNexus Gene Lab Corp (BGLC): Nasdaq/NYSE listing notice — Nasdaq grants BioNexus Gene Lab 180-day extension to meet $1 bid price rule through Nov 4, 2024

BioNexus Gene Lab Corp

Initial bid price deficiency notice received Nov 6, 2023; original 180-day cure period expired May 6, 2024.
On May 8, 2024, Nasdaq granted additional 180-day extension to regain compliance, now due by Nov 4, 2024.
To cure, closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
If not cured, Nasdaq will delist; company may request hearing before Nasdaq Hearings Panel to stay delisting.
Company states it will use reasonable efforts but cannot assure it will regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the “ Additional Period ”), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-24-002622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.